Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6139121 | 0.92 | PARP1 (0.63) | PARP1 | |
| SCHEMBL6630043 | 0.83 | PARP1 (0.38) | PARP1 | |
| Hydrochloric Acid SCHEMBL6503053 | 0.82 | PARP1 (0.38) | PARP1 | |
| SCHEMBL6203679 | 0.78 | PARP1 (0.83) | PARP1PARP2 | |
| SCHEMBL6139331 | 0.78 | PARP1 (0.55) | PARP1 | |
| Hydrochloric Acid SCHEMBL6139500 | 0.76 | PARP1 (0.55) | PARP1 | |
| SCHEMBL6199272 | 0.76 | PARP1 (0.80) | PARP1PARP2 | |
| SCHEMBL12750658 | 0.76 | PARP1 (0.65) | PARP1 | |
| SCHEMBL15515260 | 0.75 | PARP1 (0.67) | PARP1 | |
| SCHEMBL6139585 | 0.75 | PARP1 (0.71) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979683-B2 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-12-27 | — | — | US | disclosed |
| EP-1339719-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-20040029866-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029866-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CBR1, NR3C1 | PARP1 1683/4885PARP2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.